EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Epidermolysis Bullosa - Pipeline Review, H1 2015

  • ID: 3280634
  • Report
  • May 2015
  • 57 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Fibrocell Science, Inc.
  • GlaxoSmithKline plc
  • Scioderm, Inc.
  • Shire Plc
  • TWi Pharmaceuticals, Inc.
  • MORE
Epidermolysis Bullosa - Pipeline Review, H1 2015

Summary

This, ‘Epidermolysis Bullosa - Pipeline Review, H1 2015’, provides an overview of the Epidermolysis Bullosa’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Epidermolysis Bullosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Epidermolysis Bullosa and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Epidermolysis Bullosa products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Epidermolysis Bullosa pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Epidermolysis Bullosa
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Epidermolysis Bullosa pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Fibrocell Science, Inc.
  • GlaxoSmithKline plc
  • Scioderm, Inc.
  • Shire Plc
  • TWi Pharmaceuticals, Inc.
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Epidermolysis Bullosa Overview
Therapeutics Development
Pipeline Products for Epidermolysis Bullosa - Overview
Pipeline Products for Epidermolysis Bullosa - Comparative Analysis
Epidermolysis Bullosa - Therapeutics under Development by Companies
Epidermolysis Bullosa - Therapeutics under Investigation by Universities/Institutes
Epidermolysis Bullosa - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Epidermolysis Bullosa - Products under Development by Companies
Epidermolysis Bullosa - Products under Investigation by Universities/Institutes
Epidermolysis Bullosa - Companies Involved in Therapeutics Development
Fibrocell Science, Inc.
GlaxoSmithKline plc
InMed Pharmaceuticals Inc.
RegeneRx Biopharmaceuticals, Inc.
Scioderm, Inc.
Shire Plc
TWi Pharmaceuticals, Inc.
Epidermolysis Bullosa - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
diacerein - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate Collagen Type VII for Recessive Dystrophic Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GMHDFCOL-7 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ICX-RHY - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INM-750 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RGN-137 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SD-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SHP-608 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epidermolysis Bullosa - Recent Pipeline Updates
Epidermolysis Bullosa - Dormant Projects
Epidermolysis Bullosa - Discontinued Products
Epidermolysis Bullosa - Product Development Milestones
Featured News & Press Releases
Mar 19, 2015: Scioderm Initiates Phase 3 Registration Trial of Zorblisa (SD-101), a Novel Topical Therapy for Patients with Epidermolysis Bullosa
Mar 10, 2015: TWi Biotechnology Receives Rare Disease Drug Designation for its Drug Candidate AC-203 in Taiwan
Feb 03, 2015: InMed Expands Pipeline with Initiation of Program Targeting Epidermolysis bullosa simplex
Jan 02, 2015: Scioderm to Present at 33rd Annual J.P. Morgan Healthcare Conference
Oct 21, 2014: TWi Biotechnology Receives Orphan Drug Designation for its Lead Drug Candidate AC-201 In United States
Oct 06, 2014: Scioderm to Present Data from Phase 2b Study of Zorblisa (SD-101) at the 13th Annual BIO Investor Forum
Sep 09, 2014: Scioderm to Present Data from Phase 2b Study of Zorblisa (SD-101) at the debra International Congress
Jul 23, 2014: Fibrocell Science Takes Active Role to Support Dystrophic Epidermolysis Bullosa Patient Advocacy Group
Jun 13, 2014: Fibrocell Science Receives Orphan Drug Designation for Genetically-Modified Autologous Human Fibroblasts to Advance Treatment Development for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
May 28, 2014: Fibrocell Science Announces Plans for Process Development and Manufacturing of Genetically-modified Cell Therapy for Rare Disease, RDEB
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Epidermolysis Bullosa, H1 2015
Number of Products under Development for Epidermolysis Bullosa - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Epidermolysis Bullosa - Pipeline by Fibrocell Science, Inc., H1 2015
Epidermolysis Bullosa - Pipeline by GlaxoSmithKline plc, H1 2015
Epidermolysis Bullosa - Pipeline by InMed Pharmaceuticals Inc., H1 2015
Epidermolysis Bullosa - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2015
Epidermolysis Bullosa - Pipeline by Scioderm, Inc., H1 2015
Epidermolysis Bullosa - Pipeline by Shire Plc, H1 2015
Epidermolysis Bullosa - Pipeline by TWi Pharmaceuticals, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Epidermolysis Bullosa Therapeutics - Recent Pipeline Updates, H1 2015
Epidermolysis Bullosa - Dormant Projects, H1 2015
Epidermolysis Bullosa - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Epidermolysis Bullosa, H1 2015
Number of Products under Development for Epidermolysis Bullosa - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
3 of 4
- Fibrocell Science, Inc.
- GlaxoSmithKline plc
- InMed Pharmaceuticals Inc.
- RegeneRx Biopharmaceuticals, Inc.
- Scioderm, Inc.
- Shire Plc
- TWi Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll